de Haan Lieuwe, Beuk Nico, Hoogenboom Britt, Dingemans Peter, Linszen Don
Adolescent Clinic, Academic Medical Center, University ofAmsterdam, Department of Psychiatry, The Netherlands.
J Clin Psychiatry. 2002 Feb;63(2):104-7. doi: 10.4088/jcp.v63n0203.
To determine whether severity of obsessive-compulsive symptoms (OCS) differs during treatment with olanzapine or risperidone and to establish whether duration of antipsychotic treatment is related to severity of OCS.
We conducted a prospective study of consecutively hospitalized young patients (mean age = 22.4 years) with DSM-IV schizophrenia or related disorders (N = 113) who were treated with olanzapine or risperidone. Olanzapine or risperidone was randomly prescribed for patients who were drug-naive or were treated with typical antipsychotics before admission (N = 36). Patients who had started olanzapine (N = 39) or risperidone treatment (N = 23) prior to admission continued with that medication if they showed initial clinical response. Patients who prior to admission started olanzapine (N = 6) or risperidone (N = 9) but showed no response or suffered from adverse effects switched at admission to risperidone or olanzapine, respectively. Medical records, parents, and patients revealed information on duration of treatment and compliance with olanzapine or risperidone prior to admission. The Yale-Brown Obsessive Compulsive Scale (YBOCS) was administered at admission and 6 weeks thereafter.
At baseline and 6-week assessments, OCS were found in about 30% of 106 evaluable cases and 15% met DSM-IV criteria for obsessive-compulsive disorder. No differences in OCS were found in the patients randomly assigned to olanzapine or risperidone. The 35 subjects treated with olanzapine at both assessments had significantly (p = .01) more severe OCS at week 6 than the 20 subjects treated with risperidone at both assessments. Duration of treatment with olanzapine was significantly (p < .01) related to severity of OCS.
There are no differences in the short-term propensity of olanzapine or risperidone to induce or exacerbate OCS. However, severity of OCS was associated with duration of treatment with olanzapine.
确定在使用奥氮平或利培酮治疗期间,强迫症症状(OCS)的严重程度是否存在差异,并确定抗精神病药物治疗的持续时间是否与OCS的严重程度相关。
我们对连续住院的患有DSM-IV精神分裂症或相关障碍的年轻患者(平均年龄 = 22.4岁,N = 113)进行了一项前瞻性研究,这些患者接受奥氮平或利培酮治疗。奥氮平或利培酮被随机开给未用过药或入院前接受过典型抗精神病药物治疗的患者(N = 36)。入院前已开始使用奥氮平(N = 39)或利培酮治疗(N = 23)的患者,如果显示出初始临床反应,则继续使用该药物。入院前开始使用奥氮平(N = 6)或利培酮(N = 9)但无反应或出现不良反应的患者,入院时分别改用利培酮或奥氮平。病历、家长和患者提供了入院前治疗持续时间和奥氮平或利培酮依从性的信息。在入院时和此后6周进行耶鲁-布朗强迫症量表(YBOCS)评定。
在基线和6周评估时,106例可评估病例中约30%存在OCS,15%符合DSM-IV强迫症标准。随机分配接受奥氮平或利培酮治疗的患者在OCS方面未发现差异。在两次评估中均接受奥氮平治疗的35名受试者在第6周时的OCS明显(p = .01)比两次评估中均接受利培酮治疗的20名受试者更严重。奥氮平治疗的持续时间与OCS的严重程度显著(p < .01)相关。
奥氮平或利培酮在短期诱发或加重OCS方面没有差异。然而,OCS的严重程度与奥氮平治疗的持续时间有关。